deltatrials
Not Yet Recruiting PHASE2 NCT05810792

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

A Phase I/II Trial of Peri- and Postoperative Treatment With Histamine Dihydrochloride and Low-dose Interleukin-2 in Patients With Primary Resectable Pancreatic Cancer

Sponsor: Sahlgrenska University Hospital

Conditions Immunosuppression Metastasis Pancreatic Cancer Surgery
Interventions Histamine Dihydrochloride (HDC) Interleukin-2 (IL-2)
Updated 6 times since 2023 Last updated: Nov 20, 2023 Started: Apr 1, 2024 Primary completion: Apr 1, 2027 Completion: Apr 1, 2028

Listed as NCT05810792, this PHASE2 trial focuses on Immunosuppression and Metastasis and remains actively recruiting participants. Sponsored by Sahlgrenska University Hospital, it has been updated 6 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Mar 2025 — Present [monthly]

    Not Yet Recruiting PHASE2

  2. Feb 2025 — Mar 2025 [monthly]

    Not Yet Recruiting PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Not Yet Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  5. Dec 2023 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

▶ Show 1 earlier version

  1. May 2023 — Dec 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sahlgrenska University Hospital
Data source: Sahlgrenska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.